Journals / MN Kardiyoloji / 2018 / Cilt: 25 - Sayı: 2

Relationship Between Neutrophil - to - Lymphocyte Ratio and Major Adverse Cardiac Events in Patients with Saphenous Vein Graft Disease

Perkütan Koroner Girişim ile Tedavi Edilen Safen Ven Greft Hastalarında Nötrofil-Lenfosit Oranı ile Majör Advers Kardiyak Olaylar Arasındaki İlişki

Pages
77–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It can be used in this era, because it is an inexpensive and read- ily available marker that provides an additional level of risk scores in predicting in hospital and long-term outcomes in patients with saphenous vein graft disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In this study, we aimed to investigate relationship between neutrophil/lymphocyte ratio and the long term cardiovascular outcomes in saphenous vein graft disease who were revascularizated with percutaneous coronary intervention.
📊
Key Findings & Data:Material and Method: We retrospectively analyzed 98 patients (mean age 64.4±9.3 and 76% men) with significant saphenous vein graft disease whom treated with percutaneous coronary intervention.
💡
Conclusion & Impact:It can be used in this era, because it is an inexpensive and read- ily available marker that provides an additional level of risk scores in predicting in hospital and long-term outcomes in patients with saphenous vein graft disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In this study, we aimed to investigate relationship between neutrophil/lymphocyte ratio and the long term cardiovascular outcomes in saphenous vein graft disease who were revascularizated with percutaneous coronary intervention. Material and Method: We retrospectively analyzed 98 patients (mean age 64.4±9.3 and 76% men) with significant saphenous vein graft disease whom treated with percutaneous coronary intervention. Of all the participants, 42 patients experienced one or more major ad- verse cardiac events and 56 of them were free of major adverse cardiac events. Results: The median follow-up period of the study was 47.3 months. Patients with major adverse cardiac events have significantly higher neutrophil to lymphocyte ratio when compared to patients without major adverse cardiac events (3.4±1.4 vs. 2.3±0.8, p <0.001). Higher white blood cell counts, neutrophil counts, CRP levels and lower lymphocyte counts were significantly associated with major adverse cardiac events. Conclusion: Higher neutrophil /lymphocyte ratio values were associated with major adverse cardiac events in patients with saphenous vein graft disease revascularized by percutaneous coronary intervention. It can be used in this era, because it is an inexpensive and read- ily available marker that provides an additional level of risk scores in predicting in hospital and long-term outcomes in patients with saphenous vein graft disease.

Özet

Amaç: Safen ven greft hastalığında perkütan koroner girişim ile revaskülarizasyon sağlanan hastalarda işlem öncesi nötrofil lenfosit ora- nı ile uzun dönem kardiyovasküler sonuçlar arasındaki ilişkiyi değerlendirmeyi araştırdık. Gereç ve Yöntem: Safen ven grefte perkütan girişim yapılan hastalar retrospektif olarak taranarak toplamda 98 hasta; majör olumsuz kardiyak olayların varlığına (42 hasta) veya yokluğuna (56 hasta) göre iki gruba ayrıldı. Grupların işlem öncesi nötrofil lenfosit oranları karşılaştırıldı. Bulgular: Majör olumsuz kardiyak olayların olduğu grupta nötrofil lenfosit oranı, total beyaz kan hücre sayısı ve C-reaktif protein sevi- yesi majör olumsuz kardiyak olayların olmadığı gruba kıyasla anlamlı olarak yüksek bulunmuştur. Sonuç: Safen ven greft hastalığında perkütan koroner girişim öncesi nötrofil lenfosit oranları gelişebilecek kardiyovasküler olayları tah- min etmede kullanılabilen ucuz ve kolay ulaşılabilir bir belirteçtir.

🔖

Cite This Article

GÜL, M., SELÇUK, M. T., SELÇUK, H., MADEN, O., UÇAR, F. M., ŞAHAN, E., ŞEN, F. (2018). Relationship Between Neutrophil - to - Lymphocyte Ratio and Major Adverse Cardiac Events in Patients with Saphenous Vein Graft Disease. MN Kardiyoloji, Cilt: 25 - Sayı: 2, 77–82. https://ajindex.com/articles/297867

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Lee MS, Park SJ, Kandzari DE, et al. Saphenous vein graft in- tervention. JACC Car dio vasc Interv 2011;4:831-43.
  2. Bourassa MG, Fisher LD, Campeau L, Gillespie MJ, McConney M, Lespérance J. Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Mont real Heart Institute experiences. Circulation 1985; 72:V71-8 Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/ AHA/SCAI guideline for percutaneous coronary interven- tion: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:44-122.
  3. Brilakis ES, Wang TY, Rao SV, et al. Frequency and Predic - tors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovas - cular Data Cath PCI registry. JACC Cardiovasc Interv. 2010;3:1068-73
  4. Brilakis ES, Rao SV, Banerjee S, et al. Percutaneous coro- nary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry. J Am Coll Cardiol Intv 2011;4:844-50.
  5. Eagle KA, Guyton RA, Davidoff R, et al. American College of Cardiology; American Heart Association. ACC/AHA 2004 guideline update for coronary artery bypasses graft sur- gery: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guide - lines. Circulation 2004;110:340-437. Baim DS. Percutaneous treatment of saphenous vein graft disease: The ongoing challenge. J Am Coll Cardiol 2003; 42:1370-72.
  6. De Jaegere PP, Van Domburg RT, Feyter PJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996;28:89-96. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-26
  7. Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/ lymphocyte ratio with long-term mortality after ST eleva- tion myocardial infarction treated with primary percuta- neous coronary intervention. Chin Med J 2010;123:3438- 43 Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an el- evated neutrophil to lymphocyte ratio in predicting long- term mortality after percutaneous coronary intervention. Am J Cardiol 2006;97:993-96.
  8. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/ lymphocyte ratio to coronary flow to in-hospital major ad- verse cardiac events in patients with ST-elevated